Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL677798 | 0.88 | MAPK1 (0.40) | PTGS2SMN1; SMN2NPC1LMNAMAPK1 | |
| SCHEMBL127574 | 0.83 | MAPK1 (0.41) | PTGS2SMN1; SMN2NPC1LMNAMAPK1 | |
| SCHEMBL27797465 | 0.77 | ABL1 (0.44) | SMN1; SMN2NPC1LMNAMAPK1CASP3 | |
| SCHEMBL31510648 | 0.72 | HNF4A (0.43) | SMN1; SMN2NPC1LMNAMAPK1CASP3 | |
| SCHEMBL26632610 | 0.72 | HNF4A (0.43) | SMN1; SMN2NPC1LMNAMAPK1CASP3 | |
| SCHEMBL6342144 | 0.71 | PPARG (0.35) | PTGS2SMN1; SMN2NPC1LMNAMAPK1 | |
| SCHEMBL6342141 | 0.71 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1LMNAMAPK1CASP3 | |
| SCHEMBL10524404 | 0.71 | PTGS2 (0.37) | PTGS2SMN1; SMN2MAPK1PDCD1CD274 | |
| SCHEMBL9695975 | 0.70 | PDCD1 (0.37) | SMN1; SMN2NPC1LMNAMAPK1CASP3 | |
| SCHEMBL22432024 | 0.70 | NOTUM (0.39) | SMN1; SMN2NPC1LMNAMAPK1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005112883-A1 | PRESERVED PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLODEXTRINS | ALLERGAN, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-6969706-B1 | Preserved pharmaceutical compositions comprising cyclodextrins | ALLERGAN, INC. (US) | 2005-11-29 | — | — | US | disclosed |
| US-20050256083-A1 | Ophthalmic liquid containing a cyclodextrin, a guanidine-based cationic compound, and sorbic acid | ALLERGAN, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| US-20040214797-A1 | Preserved pharmaceutical compositions comprising cyclodextrins | ALLERGAN, INC. | 2004-10-28 | — | — | US | disclosed |
| EP-0877600-B1 | PRESERVATIVE SYSTEMS FOR PHARMACEUTICAL COMPOSITIONS CONTAINING CYCLODEXTRINS | ALCON MFG LTD (US) | 2003-10-22 | — | — | EP | disclosed |
| US-5985310-A | CHELATING AGENT AND AN ANTIMICROBIAL PRESERVATIVE WHICH IS BORIC ACID AND A COMPOUND SELECTED FROM BENZALKONIUM HALIDE COMPOUNDS, POLYMERIC QUATERNARY AMMONIUM COMPOUNDS, AND QUATEMARY AMMONIUM ALKYLENE GLYCOL PHOSPHOLIPID DERIVATIVES | ALCON LABORATORIES, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| EP-0877600-A1 | PRESERVATIVE SYSTEMS FOR PHARMACEUTICAL COMPOSITIONS CONTAINING CYCLODEXTRINS | ALCON LABORATORIES, INC. (US) | 1998-11-18 | — | — | EP | disclosed |
| WO-1998006381-A1 | PRESERVATIVE SYSTEMS FOR PHARMACEUTICAL COMPOSITIONS CONTAINING CYCLODEXTRINS | ALCON LABORATORIES, INC. (US) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214797-A1 | Preserved pharmaceutical compositions comprising cyclodextrins | DDOST, RPN1, GANC | PTGS2 975/4885SMN1; SMN2 3173/4885NPC1 726/4885 |
| US-20050256083-A1 | Ophthalmic liquid containing a cyclodextrin, a guanidine-based cationic compound, and sorbic acid | SORBS1, GANC, UACA | PTGS2 2711/4885SMN1; SMN2 1857/4885NPC1 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.